Insider · CIK 1237564

Steven M Paul

  • Director at Rapport Therapeutics RAPP: 1 buys, 0 sales
  • President & CEO at Karuna Therapeutics: 2 buys, 0 sales
Open-market buys3
Open-market sales0
Bought$1.2M
Sold$0

Every trade, with what the company filed around it

Open-market buys and sales as each Form 4 states them, newest first.

How these figures work

Notes on each row are as each Form 4 states them, next to SEC Tracker's own records of the company's filings and other insiders' buys. Holding after is what the filing reports they held after the trade, with the change in their holding.

DateCompanyTradeValueHolding afterNotes
Oct 22, 2026Rapport Therapeutics RAPPBought 35,714 sh at $27.28
Their first open-market buy here in SEC Tracker's records. One of 6 insiders who bought $1.7M over 3 days, within the 30-day window. 2 days after the company's 8-K filed Oct 20, 2026.
$974K77,380 +86%
Their first open-market buy here in SEC Tracker's records. One of 6 insiders who bought $1.7M over 3 days, within the 30-day window. 2 days after the company's 8-K filed Oct 20, 2026.
Aug 18, 2021Karuna TherapeuticsBought 1,181 sh at $106.10
168 days after the company's 8-K filed Mar 3, 2021.
$125K108,849 +1%
168 days after the company's 8-K filed Mar 3, 2021.
Aug 17, 2021Karuna TherapeuticsBought 1,183 sh at $105.63
Their first open-market buy here in SEC Tracker's records. 167 days after the company's 8-K filed Mar 3, 2021.
$125K107,668 +1%
Their first open-market buy here in SEC Tracker's records. 167 days after the company's 8-K filed Mar 3, 2021.

Open-market trades are Form 4 transaction codes P (purchase) and S (sale). Planned sales are those the filing marks as made under a Rule 10b5-1 plan. A P-code buy at the offering price within a day of the company's FWP, 424B prospectus or offering 8-K is marked Bought in the offering and left out of open-market buy counts and cluster buys. Prices and values are as stated in each Form 4. Stock prices aren't shown on this page. Not investment advice.